Jump to content

CSPG4

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Boghog (talk | contribs) at 16:43, 18 April 2018 (consistent citation formatting and removed further reading citations not specific to this gene). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

CSPG4
Identifiers
AliasesCSPG4, HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16, NG2, chondroitin sulfate proteoglycan 4, CSPG4A
External IDsOMIM: 601172; MGI: 2153093; HomoloGene: 20445; GeneCards: CSPG4; OMA:CSPG4 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1464

121021

Ensembl

ENSG00000173546

ENSMUSG00000032911

UniProt

Q6UVK1

Q8VHY0

RefSeq (mRNA)

NM_001897

NM_139001

RefSeq (protein)

NP_001888

NP_620570

Location (UCSC)Chr 15: 75.67 – 75.71 MbChr 9: 56.77 – 56.81 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Chondroitin sulfate proteoglycan 4, also known as melanoma-associated chondroitin sulfate proteoglycan (MCSP) or neuron-glial antigen 2 (NG2), is a chondroitin sulfate proteoglycan that in humans is encoded by the CSPG4 gene.[5][6][7]

CSPG4 plays a role in stabilizing cell-substratum interactions during early events of melanoma cell spreading on endothelial basement membranes. It represents an integral membrane chondroitin sulfate proteoglycan expressed by human malignant melanoma cells.[7]

CSPG4/NG2 is also a hallmark protein of oligodendrocyte progenitor cells (OPCs)[8] and OPC dysfunction has been implicated as a candidate pathophysiological mechanism of familial schizophrenia.[9] A research group investigating the role of genetics in schizophrenia, reported, two rare missense mutations in CSPG4 gene, segregating within families (CSPG4A131T and CSPG4V901G mutations). The researchers also demonstrate that the induced pluripotent stem cells (iPSCs)-derived OPCs from CSPG4A131T mutation carriers exhibited abnormal post-translational processing, subcellular localization of the mutant NG2 protein, aberrant cellular morphology, and a decreased cell viability and myelination potential. In vivo diffusion tensor imaging of the brain of CSPG4A131T mutation carriers demonstrated a reduced white matter integrity compared to the unaffected sibling and matched general population controls.[10]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000173546 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000032911 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA (September 1996). "Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan". Proceedings of the National Academy of Sciences of the United States of America. 93 (18): 9710–5. doi:10.1073/pnas.93.18.9710. PMC 38494. PMID 8790396.
  6. ^ Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S (May 2006). "Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells". Oncogene. 25 (20): 2873–84. doi:10.1038/sj.onc.1209319. PMID 16407841.
  7. ^ a b "Entrez Gene: CSPG4 chondroitin sulfate proteoglycan 4".
  8. ^ Nishiyama A, Dahlin KJ, Prince JT, Johnstone SR, Stallcup WB (July 1991). "The primary structure of NG2, a novel membrane-spanning proteoglycan". The Journal of Cell Biology. 114 (2): 359–71. PMC 2289079. PMID 1906475.
  9. ^ de Vrij FM, Bouwkamp CG, Gunhanlar N, Shpak G, Lendemeijer B, Baghdadi M, Gopalakrishna S, Ghazvini M, Li TM, Quadri M, Olgiati S, Breedveld GJ, Coesmans M, Mientjes E, de Wit T, Verheijen FW, Beverloo HB, Cohen D, Kok RM, Bakker PR, Nijburg A, Spijker AT, Haffmans PM, Hoencamp E, Bergink V, Vorstman JA, Wu T, Olde Loohuis LM, Amin N, Langen CD, Hofman A, Hoogendijk WJ, van Duijn CM, Ikram MA, Vernooij MW, Tiemeier H, Uitterlinden AG, Elgersma Y, Distel B, Gribnau J, White T, Bonifati V, Kushner SA (January 2018). "Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia". Molecular Psychiatry. doi:10.1038/s41380-017-0004-2. PMID 29302076.
  10. ^ de Vrij FM, Bouwkamp CG, Gunhanlar N, Shpak G, Lendemeijer B, Baghdadi M, Gopalakrishna S, Ghazvini M, Li TM, Quadri M, Olgiati S, Breedveld GJ, Coesmans M, Mientjes E, de Wit T, Verheijen FW, Beverloo HB, Cohen D, Kok RM, Bakker PR, Nijburg A, Spijker AT, Haffmans PM, Hoencamp E, Bergink V, Vorstman JA, Wu T, Olde Loohuis LM, Amin N, Langen CD, Hofman A, Hoogendijk WJ, van Duijn CM, Ikram MA, Vernooij MW, Tiemeier H, Uitterlinden AG, Elgersma Y, Distel B, Gribnau J, White T, Bonifati V, Kushner SA (January 2018). "Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia". Molecular Psychiatry. doi:10.1038/s41380-017-0004-2. PMID 29302076.

Further reading

Stub icon

This article on a gene on human chromosome 15 is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CSPG4&oldid=837086601"